10-Q quarterly report · filed Nov 12, 2026

Kodiak Sciences Inc. (KOD) Q3 2026 10-Q Quarterly Report

Short answer

Kodiak Sciences Inc. (KOD) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$66M
−7.8% YoY · −0.9% QoQ
EPS (diluted)
−$1.05
+9.5% YoY · +0.0% QoQ

Source: XBRL data from the Kodiak Sciences Inc. (KOD) Q3 2026 10-Q on SEC EDGAR. USD.

Kodiak Sciences Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • No product revenue, compared with no product revenue in the same quarter last year
  • Operating loss $67.1M vs $62.4M YoY, net loss $66.2M vs $61.5M
  • Worst program trend: KSI-101 expenses $11.7M vs $2.6M, up $9.1M YoY
  • Cash $88.7M at September 30, 2026, operating cash used $130.1M through nine months
  • $68.9M net ATM proceeds after quarter-end, $280.4M remaining availability; BLA submission planned for Zenkuda in fourth quarter 2026

Risk Factors

  • No material changes identified: risk factors appear substantially carried forward from the 10-K
  • Clinical efficacy risk: tarcocimab failed primary non-inferiority endpoints in DAZZLE, GLEAM and GLIMMER
  • Regulatory risk: 2024 Loper Bright decision may increase challenges to FDA regulations and create approval uncertainty
  • Market risk: Eylea HD gained FDA approval for RVO in November 2025, intensifying retinal-treatment competition
  • Supply-chain risk: tarcocimab, KSI-501 and KSI-101 rely on single-source suppliers across China, Japan, UK, US and Switzerland

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Kodiak Sciences Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.